Lexington Biosciences (LXGTF) Stock Statistics & Valuation Metrics

Lexington Biosciences has a market cap or net worth of $218.97K. The enterprise value is ―.

Lexington Biosciences has 3,786,840 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lexington Biosciences’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Lexington Biosciences is ―. Lexington Biosciences’s PEG ratio is ―.

In the last 12 months, Lexington Biosciences had revenue of 0.00 and earned ― in profits. Earnings per share was 0.00.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Lexington Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Lexington Biosciences upcoming earnings date is Nov 29, 2022, TBA Not Confirmed.

Lexington Biosciences as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, Lexington Biosciences has paid 0.00 in taxes.

Lexington Biosciences EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Lexington Biosciences has $0.00 in cash and marketable securities with C$872.25K in debt, giving a net cash position of $0.00 billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for Lexington Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―